Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2898MR)

This product GTTS-WQ2898MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2898MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ919MR IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-221
GTTS-WQ14422MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ15696MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ3784MR IVTScrip™ mRNA-Anti-Factor VIIa substitute, BAY-86-6150(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY-86-6150
GTTS-WQ5050MR IVTScrip™ mRNA-Anti-GLP1R, CA Exendin-4(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CA Exendin-4
GTTS-WQ13114MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-03446962
GTTS-WQ3628MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ6847MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA DT-IL-3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW